Navigation Links
ASCP Joins ACLU Lawsuit Opposing Gene Patents
Date:5/13/2009

The American Society for Clinical Pathology (ASCP) has joined the American Civil Liberties Union (ACLU) in a lawsuit challenging the legality of patents on human genes -- specifically, patents covering the BRCA1 and BRCA2 genes, which are associated with breast and ovarian cancer. The lawsuit was filed against the U.S. Patent and Trademark Office, Myriad Genetics, and Directors of the University of Utah Research Foundation in U.S. District Court in the Southern District of New York on May 12.

(Vocus) May 13, 2009 -- The American Society for Clinical Pathology (ASCP) has joined the American Civil Liberties Union (ACLU) in a lawsuit challenging the legality of patents on human genes -- specifically, patents covering the BRCA1 and BRCA2 genes, which are associated with breast and ovarian cancer. The lawsuit (Case 1:09-cv-04515-RWS Association For Molecular Pathology et al v. United States Patent and Trademark Office et al Complaint) was filed against the U.S. Patent and Trademark Office, Myriad Genetics, and Directors of the University of Utah Research Foundation in U.S. District Court in the Southern District of New York on May 12.

"ASCP joined this lawsuit because a fundamental tenet of ASCP is that patients come first," said ASCP President Barbara J. McKenna, MD, FASCP. "Gene patents violate this principle by creating unjustifiable monopolies on human genetic information that is critical in the diagnosis of many diseases."

ASCP further asserts that gene patents limit the broad availability of diagnostic tests due to the simple fact that laboratory scientists are prohibited from performing genetic tests because of patent enforcement and the threat of litigation.

As a result, the market is dominated by a single provider, eliminating competition and scientific diversity, which ultimately drives up costs. Gene patents potentially infringe on patients' rights, denying them access to their own genetic information. Such patents stifle the innovative process, negating further refinement in test methodology, improvements in quality, and access to testing for the uninsured as well as those whose health care coverage requires that testing be reimbursed by a third-party payer.

"In short, the practice of gene patenting harms patients, impedes advances in medicine, and limits those in the practice of pathology and laboratory medicine from doing what they are educated to do -- provide high quality health care and engage in research that will enhance the practice of medicine and patient care," Dr. McKenna said.

The lawsuit states the patents restrict ease of access by giving Myriad the right to prevent clinicians from independently looking at or interpreting a person's BRCA1 and BRCA2 genes to determine if the person is at a higher risk of breast and/or ovarian cancer.

Women who fear they may be at an increased risk of breast and/or ovarian cancer do not have the option to have anyone look at their BRCA1 and BRCA2 genes or interpret them except for the patent holder. Women are thereby prevented from obtaining information about their health risks from anyone other than the patent holder, whether as an initial matter or to obtain a second opinion.

The patents also prevent doctors or laboratories from independently offering testing to their patients, externally validating the test, or working cooperatively to improve testing. Many women at risk cannot even be tested because they are uninsured and/or cannot afford the test offered by Myriad.

"Genes are not inventions like new treatments, drugs, diagnostic tests or technology platforms," said Dr. McKenna. "They are products of nature that exist in all our bodies. No one deserves exclusive patent rights when all they did was uncover something that nature created or that nature does. Einstein couldn't get a patent on E=mc² even though he worked very hard to discover it."

More information and the full complaint are available at www.aclu.org/brca. For more information on ASCP visit www.ascp.org.

###

Read the full story at http://www.prweb.com/releases/ascp/gene_patents/prweb2417834.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
2. Andre Marion Joins Microchip Biotechnologies Board of Directors
3. Shane Lyons Joins GenVault Corporation as Vice President of Sales and Marketing
4. Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company
5. Richard Giltner Joins United Therapeutics Board of Directors
6. Chad Ronholdt Joins LABS Inc.
7. Surety, LLC Joins Microsoft BioIT Alliance
8. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
9. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
10. Chimerix Joins International Network of Organizations to Cure Malaria
11. Van Andel Institute Joins the MetaMiner Oncology Partnership Program
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ASCP Joins ACLU Lawsuit Opposing Gene Patents
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), The Molecular ... with the launch of the SureSeq myPanel™ NGS Custom FH ... familial hypercholesterolemia (FH). The panel delivers single nucleotide variation (SNV) ... panel and allows customisation by ,mix and match, of fully-optimised ... LDLR , P C SK9 , ...
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
(Date:12/8/2016)... Dec. 8, 2016 Eutilex Co. Ltd. today ... (US $18.9M) Series A financing. This financing round included ... Venture and SNU Bio Angel. This new funding brings ... KRW (US $27.7M) since its founding in 2015. ... the development and commercialization of its immuno-oncology programs, expand ...
Breaking Biology Technology:
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... offering of €500.0 million principal amount of its 1.414% senior ... its 2.425% senior unsecured notes due 2026. ... December 13, 2016, subject to the satisfaction of customary closing conditions.  ... The Company intends to use the ...
(Date:12/5/2016)... 5, 2016  The Office of Justice Programs, ... CT Scans Enhance or Replace Medico Legal Autopsies?" ... supporting or replacing forensic autopsies with postmortem X-ray ... In response to recommendations made by The ... CT scans as a potential component of medicolegal ...
Breaking Biology News(10 mins):